This message was posted by a user wishing to remain anonymous
If there is a minor formulation change in a fluid path component of a parenteral infusion bag, what testing is required of the filling pharmacy to evaluate the change? Is there a USP chapter that provides guidance on this point?
If the bag manufacturer has validated the formulation change does not affect functionality of the bag nor biocompatibility, can the pharmacy use this as a basis for not repeating extensive stability testing?